Associations - Tecentriq (atezolizumab)

PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
HR negative + PD-L1 expression	HER2 Negative Breast Cancer	HR negative + PD-L1 expression	HER2 Negative Breast Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	atezolizumab + cobimetinib Resistant: A2 - Guideline atezolizumab + cobimetinib Resistant : A2	atezolizumab + cobimetinib Resistant: A2 - Guideline atezolizumab + cobimetinib Resistant : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B

Tecentriq (atezolizumab)

Associations
(236)

Associations
(236)

Tecentriq (atezolizumab)

Associations(236)

Associations(236)

Associations
(236)

Associations
(236)